Kytril Inj/Inf (Granisetron)

Granisetron works by selectively blocking serotonin 5‑HT3 receptors located in the gastrointestinal tract and the brain's chemoreceptor trigger zone. By inhibiting these receptors, it stops the transmission of emetic signals that are triggered by chemotherapy, radiation, or surgical stress, thereby reducing the sensation of nausea and the reflex of vomiting.

The specific dose of Kytril Inj/Inf is determined by the prescribing clinician based on the patient’s age, weight, type of chemotherapy or surgery, and overall clinical condition. The prescriber will select the appropriate volume and concentration for intravenous administration according to approved guidelines and individual patient needs.

Safety data for granisetron during pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should evaluate each case individually and discuss potential risks and alternatives with the patient.

To order Kytril Inj/Inf, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After submission, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if required), and import documentation.

Both Kytril (granisetron) and ondansetron belong to the 5‑HT3 antagonist class and share a similar mechanism of blocking serotonin receptors. Granisetron has a longer half‑life, which may allow less frequent dosing, while ondansetron is available in oral and injectable forms. Choice of agent often depends on clinical protocol, patient tolerance, and specific drug‑interaction considerations.

Kytril Inj/Inf must be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Before use, inspect for particulate matter or discoloration and discard any product that appears compromised.

Kytril Inj/Inf is administered by intravenous injection or infusion, usually over a short period (often 2‑5 minutes) before the start of chemotherapy or surgery. The exact administration technique, rate, and timing are determined by the treating physician and nursing staff according to institutional protocols.

The most serious risks include cardiac arrhythmias such as QT interval prolongation, severe allergic reactions (anaphylaxis), and rare cases of serotonin syndrome. Patients with known cardiac disease, electrolyte abnormalities, or those taking other QT‑prolonging medications should be monitored closely during treatment.

Kytril Inj/Inf should be avoided in patients with a known hypersensitivity to granisetron or any component of the formulation. Caution is also advised for individuals with significant cardiac conduction disorders, prolonged QT interval, or those receiving concurrent medications that markedly prolong the QT interval.